El mercado de inmunoglobulinas intravenosas se valoró en 11.206,54 millones de dólares en 2021 y es probable que alcance un valor de 18.672,55 millones de dólares en 2028; se estima que crecerá a una tasa compuesta anual del 7,6 % entre 2022 y 2028.
Las inmunoglobulinas son anticuerpos producidos naturalmente por el sistema inmunológico del cuerpo, que ayudan a combatir infecciones y enfermedades. La deficiencia de inmunoglobulina requiere la administración externa de inmunoglobulina y se conoce como terapia de reemplazo de inmunoglobulina (IgRT). La IgRT se puede administrar por vía intravenosa y subcutánea. La inmunoglobulina intravenosa (IVIg) y la inmunoglobulina subcutánea (SCIg) se seleccionan según la indicación y la gravedad. La IgIV se fabrica a partir de plasma humano. Contiene anticuerpos y se utiliza para tratar un número creciente de enfermedades inmunológicas, hematológicas y neurológicas.
Perspectivas estratégicas
El mercado de inmunoglobulinas intravenosas está segmentado por tipo, aplicación, canal de distribución, usuario final y geografía. Por geografía, el mercado está ampliamente segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y Asia. África y el Sur y el Sur. Centroamérica. Este informe ofrece información y un análisis en profundidad del mercado, enfatizando parámetros como las tendencias del mercado, la dinámica del mercado y el análisis competitivo de los principales actores del mercado a nivel mundial.
< h3>regiones lucrativas para el mercado de inmunoglobulinas intravenosasPerspectivas del mercado
La creciente prevalencia de enfermedades de inmunodeficiencia y el aumento de la población geriátrica están impulsando el mercado de inmunoglobulinas intravenosas.
Según el Instituto Nacional de Alergias y Enfermedades Infecciosas (NIAID), más de 200 tipos diferentes de enfermedades de inmunodeficiencia primaria (PIDD) afectan a unas 500.000 personas en los EE. UU. Las enfermedades genéticas raras pueden ser crónicas, débiles y costosas. La trombocitopenia inmunitaria (PTI) es un trastorno hemorrágico autoinmune caracterizado por niveles anormalmente bajos de plaquetas; una situación conocida como trombocitopenia. Según la Organización de Enfermedades Raras, cada año se registran en todo el mundo unos 200.000 casos de PTI. Además, según la División de Población de las Naciones Unidas, World Population Prospects 2019, los países asiáticos y europeos tienen algunas de las poblaciones más ancianas del mundo, de 65 años o más. Japón está a la cabeza con un 28%, seguido de Italia con un 23%. Además, Finlandia, Portugal y Grecia se encuentran entre los cinco países con una población de edad inferior al 22%. Muchos de los pacientes tratados con IVIG tienen más de 60 años. Con el envejecimiento, la capacidad de producir células T para combatir enfermedades se reduce significativamente. Por lo tanto, el cuerpo de una persona mayor es fácilmente propenso a varias infecciones y enfermedades, lo que aumenta la demanda de terapias inmunitarias que impliquen el uso de IgIV. Por lo tanto, el aumento de las enfermedades de inmunodeficiencia y el aumento de la población geriátrica en todo el mundo está impulsando el mercado de inmunoglobulinas intravenosas.
Información basada en tipos
Según el tipo, el mercado de inmunoglobulinas intravenosas se segmenta en IgG, IgM, IgA, IgE e IgD. El segmento de inmunoglobulinas de tipo IgG tuvo la mayor participación de mercado en 2021. Sin embargo, se prevé que el segmento portátil registre la CAGR más alta durante el período de pronóstico debido a su amplia aplicación de IgG en el tratamiento de varias categorías de trastornos.
Mercado de inmunoglobulinas intravenosas, por tipo: 2021 y 2028
Información basada en aplicaciones
Según la aplicación, el mercado de inmunoglobulinas intravenosas se segmenta en hipogammaglobulinemia, polineuropatía desmielinizante inflamatoria crónica, enfermedades de inmunodeficiencia, miastenia gravis, neuropatía motora multifocal, púrpura trombocitopénica idiopática, miopatías inflamatorias, deficiencia de anticuerpos específicos, síndrome de Guillain-Barré y otros. En 2021, el segmento de enfermedades de inmunodeficiencia tuvo la mayor participación del mercado. Además, se espera que el mismo segmento experimente un crecimiento en su demanda a la CAGR más rápida de 2022 a 2028 debido a la creciente prevalencia de enfermedades de inmunodeficiencia y al aumento de las aprobaciones de la FDA para productos IgIV para tratar la inmunodeficiencia.
Canal de distribución- Información basada en
Según el canal de distribución, el mercado de inmunoglobulinas intravenosas se segmenta en farmacia hospitalaria, farmacia minorista y otros. En 2021, el segmento de farmacia hospitalaria ocupó la mayor cuota de mercado. Además, se espera que el segmento de farmacias minoristas experimente un crecimiento en su demanda a la CAGR más rápida de 2022 a 2028, debido a las expansiones de las farmacias minoristas y el cambio en el comportamiento de los consumidores hacia farmacias minoristas organizadas que ofrecen fármacos y medicinas de alta calidad. /p>
Información basada en el usuario final
Según el usuario final, el mercado de inmunoglobulinas intravenosas se segmenta en hospitales, clínicas especializadas y otros. En 2021, el segmento de hospitales tuvo la mayor participación del mercado. Además, se espera que el segmento de clínicas especializadas experimente un crecimiento en la demanda a la CAGR más rápida de 2022 a 2028, debido a los avances en las clínicas especializadas para ofrecer IgRT rápida y precisa a los pacientes.
Desarrollos orgánicos como el producto Las aprobaciones son estrategias altamente adoptadas por los actores del mercado global de inmunoglobulinas intravenosas. A continuación se enumeran algunos de los desarrollos clave recientes del mercado:
- En marzo de 2022, ADMA Biologics, Inc. anunció la aprobación de la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) para extender el caducidad que data de 24 a 36 meses para su producto farmacéutico de inmunoglobulina (“IG”) ASCENIV y BIVIGAM almacenado a 2-8°C. La extensión de la fecha de vencimiento se aplica a todos los lotes de ASCENIV y BIVIGAM existentes actualmente en la cadena de suministro comercial, así como a la producción futura de ASCENIV y BIVIGAM en todos los tamaños de viales, escalas de producción y productos farmacéuticos terminados para llenado interno y externo.
- En junio de 2021, Octapharma anunció que octagam 10%, una inmunoglobulina intravenosa derivada de plasma humano (IgIV), había obtenido recientemente la aprobación en la Unión Europea (UE) como terapia inmunomoduladora para adultos con dermatomiositis. Tras la aprobación de la UE, octagam 10% recibió la aprobación nacional en Alemania el 11 de mayo de 2021, y se espera la aprobación pronto en otros estados miembros europeos.
- En abril de 2021, ADMA Biologics, Inc. anunció que el US Food y la Administración de Medicamentos (“FDA”) aprobaron el proceso de fabricación ampliado de la compañía, lo que permite el fraccionamiento y la purificación de una mezcla de plasma de 4400 litros para la fabricación de inmunoglobulina intravenosa (“IVIG”).
- En febrero de 2020, CSL Behring anunció que la Administración de Medicamentos y Alimentos de EE. UU. (FDA) otorgó a Privigen (inmunoglobulina intravenosa (humana), 10% líquida) la designación de medicamento huérfano como terapia en investigación en el tratamiento de la esclerosis sistémica (ES). /li>
Estos desarrollos por parte de los actores del mercado están impulsando el mercado de las inmunoglobulinas intravenosas.
Inmunoglobulina intravenosa – ndash; Segmentación del mercado
El mercado mundial de inmunoglobulinas intravenosas está segmentado por tipo, aplicación, canal de distribución, usuario final y geografía. Según el tipo, el mercado se segmenta en IgG, IgM, IgA, IgE e IgD). Por aplicación, el mercado se segmenta en hipogammaglobulinemia, polineuropatía desmielinizante inflamatoria crónica, enfermedades de inmunodeficiencia, miastenia gravis, neuropatía motora multifocal, púrpura trombocitopénica idiopática, miopatías inflamatorias, deficiencia de anticuerpos específicos, síndrome de Guillain-Barré y otros. Según el canal de distribución, el mercado se segmenta en farmacia hospitalaria, farmacia minorista y otros. Por Usuario Final, el mercado se segmenta en hospitales, clínicas especializadas y otros. Por geografía, el mercado está segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y Asia. África y el Sur y el Sur. Centroamérica.
Perfiles de empresas
- Takeda Pharmaceutical Company Limited
- Grifols, SA
- Pfizer Inc. < li>ADMA Biologics Inc.
- Bio Products Laboratory Ltd.
- Shanghai RAAS
- Octapharma AG
- Kedrion SpA < li>CSL Behring (CSL Limited)
- Prothya Biosolutions BV
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Immunoglobulins are the antibodies produced naturally by the body’s immune system, which help fight infection and disease. The deficiency of immunoglobulin requires the external administration of immunoglobulin and known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIg is manufactured from human plasma. It contains antibodies and is used in the treatment of a growing number of immunologic, hematologic and neurologic illnesses.
The IgG segment under type segment, held the largest share in 2021.
The intravenous immunoglobulin market majorly consists of the players such as Takeda Pharmaceutical Company Limited; Grifols, S.A.; Pfizer Inc.; ADMA Biologics Inc.; Bio Products Laboratory Ltd.; Shanghai RAAS; Octapharma AG; Kedrion S.p.A; CSL Behring (CSL Limited); and Prothya Biosolutions B.V.
Based on geography, the APAC region is accounted for highest CAGR in intravenous immunoglobulin market during the forecast period.
The List of Companies - Intravenous Immunoglobulin Market
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Pfizer Inc.
- ADMA Biologics Inc.
- Bio Products Laboratory Ltd.
- Shanghai RAAS
- Octapharma AG
- Kedrion S.p.A
- CSL Behring (CSL Limited)
- Prothya Biosolutions B.V.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Aug 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Aug 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Aug 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)